betfirso

Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceuticals comprising small molecules; small molecule compounds for medical use and drug delivery; small molecule pharmaceuticals for the treatment of diseases and conditions; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders; antibodies sold as a component ingredient of pharmaceuticals; diagnostic preparations for medical purposes; biological substances for human medical diagnostics and analysis; clinical medical reagents; biological preparations for medical purposes; pharmaceutical and veterinary preparations, agents and substances.